Teens on GLP-1 drugs: are their bones at risk?
NCT ID NCT06903923
First seen Jun 24, 2026 · Last updated Jun 27, 2026 · Updated 1 time
Summary
This study tracks bone health in 120 teens aged 12–21 with obesity who are either starting a GLP-1 drug (like semaglutide) or following lifestyle changes. Over 24 months, researchers measure bone density and strength using scans and lab tests. The goal is to see if these popular weight-loss drugs affect growing bones.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
- Active substance
- GLP-1 receptor agonist (e.g., liraglutide, semaglutide)
- What this could lead to
- If successful, this study could show whether GLP-1 drugs affect bone strength in teens, helping doctors make safer treatment choices.
- What could go wrong
- This is a small, early-phase observational study, not a large trial. Results may not apply to all teens, and bone changes may take longer to appear.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for BONE DENSITY are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Locations
-
University of Virginia Medical Center
RECRUITINGCharlottesville, Virginia, 22903, United States
More trials for these conditions
Other studies related to the condition(s) this trial covers.
- Can a natural compound help preserve jawbone after tooth loss?
- Can a new stomach and gut bypass surgery tackle obesity and diabetes?
- Can a Two-Drug combo tip the scales against obesity?
- Can Weight-Loss surgery change how medications work?
- Coffee grounds probiotic could reshape gut health and fight inflammation
- Can shedding pounds reboot the Heart's exercise engine?